Pharma Capital

Cellmid's Maria Halasz buys shares on market

Maria Halasz has increased her shareholding through buying on market.
cellmid-mariahalasz-presenting-sydney-luncheon-3-aug-757.jpg
Cellmid shares are up 15% in 2017 trading at $0.03

Cellmid (ASX:CDY) has had its managing director and CEO, Maria Halasz, purchase 400,000 shares on market recently.

This takes Halasz’s Total direct and indirect holding to 27.3 million shares.

Total consideration for the 400,000 shares purchased amounted to $11,600 for an average price of $0.029.

Cellmid has two business segments, consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio.

Cellmid recorded a 79% increase in December quarter hair loss product sales compared with the prior December quarter and will enter 2017 with a healthy $5.3 million in cash.



Register here to be notified of future CDY Company articles
View full CDY profile

Cellmid Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.